US 12,071,440 B2
Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
Anna Ericsson, Shrewsbury, MA (US); Neal Green, Newton, MA (US); Gary Gustafson, Ridgefield, CT (US); Bingsong Han, Westwood, MA (US); David R. Lancia, Jr., Boston, MA (US); Lorna Mitchell, West Beach (AU); David Richard, Littleton, MA (US); Tatiana Shelekhin, Ridgefield, CT (US); Chase C. Smith, Rutland, MA (US); Zhongguo Wang, Lexington, MA (US); and Xiaozhang Zheng, Lexington, MA (US)
Assigned to Novo Nordisk Health Care AG, Zurich (CH)
Filed by Novo Nordisk Health Care AG, Zurich (CH)
Filed on Mar. 21, 2023, as Appl. No. 18/124,071.
Application 18/124,071 is a continuation of application No. 17/239,364, filed on Apr. 23, 2021, granted, now 11,649,242.
Application 17/239,364 is a continuation of application No. 16/496,279, granted, now 11,014,927, issued on May 25, 2021, previously published as PCT/US2018/023405, filed on Mar. 20, 2018.
Claims priority of provisional application 62/473,751, filed on Mar. 20, 2017.
Prior Publication US 2024/0083901 A1, Mar. 14, 2024
Int. Cl. A61K 31/407 (2006.01); A61K 9/00 (2006.01); A61P 7/00 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 9/0053 (2013.01); A61K 31/407 (2013.01); A61P 7/00 (2018.01); C07D 519/00 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A compound of formula

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.